Abstract Library

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,

#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)

Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Levy S, van Veenendaal L, Korse C, Verbeek W, Vriens M,

Keywords: SI-NET, Nomogram, Survival,

#2913 The Predictive Value of Neuroendocrine Transcript Analysis in Daily Practice: An Independent ‘Real-World’ Validation Study

Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Treijen M

Authors: van Treijen M, van der Zee D, Heeres B, Staal F, Vriens M,

Keywords: biomarker, progression-free survival, gastro-entero-pancreatic neuroendocrine tumours,

#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin

Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hackeng W, Geisenberger C, de Leng W, Morsink F, Vriens M,

Keywords: Methylation profiling, Neuroendocrine tumor, Machine Learning, Unknown Primary,

#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement

Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Pieterman* C, De Herder* W, Vriens M, Van Goor H, Nieveen van Dijkum E,

Keywords: multiple endocrine neoplasia type 1, duodenopancreatic neuroendocrine tumors,, insulinoma, gastrinoma, non-functioning pancreatic neuroendocrine tumors, consensus, surgery ,